Positive Top-Line Phase 3 Results for Novel Myasthenia Gravis Drug Positive Top-Line Phase 3 Results for Novel Myasthenia Gravis Drug

The novel self-administered subcutaneous peptide inhibitor zilucoplan met the primary and all secondary endpoints in a phase 3 study of adults with generalized myasthenia gravis.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news